FINWIRES · TerminalLIVE
FINWIRES

Solid Biosciences Says SGT-003 Gets EU Orphan Drug Designation for Duchenne Muscular Dystrophy

By

-- Solid Biosciences (SLDB) said Tuesday the European Commission has granted orphan drug designation to its investigational therapy SGT-003 for Duchenne muscular dystrophy.

This decision followed a positive recommendation from the European Medicines Agency's Committee for Orphan Medicinal Products, the company said.

SGT-003 already has been granted fast track, orphan drug, and rare pediatric disease designations by the US Food and Drug Administration, the company said, adding that the therapy is currently being tested in two clinical trials aimed at supporting regulatory approval in different countries.

Price: $7.54, Change: $+0.04, Percent Change: +0.47%

Related Articles

Equities

Earnings Flash (VIST) Vista Energy Posts Q1 Adjusted EPS $0.89

$VIST
Equities

Earnings Flash (VIST) Vista Energy Posts March Quarter Revenue $865.0M

$VIST
Mining & Metals

Capstone Copper Q1 Profit Jumps Nearly 12-Fold, Beats Estimates On Higher Copper Prices

Capstone Copper (CS.TO) after the close Wednesday reported a nearly 12-fold surge in first-quarter adjusted net income as higher copper prices boosted earnings, with results topping analysts' estimates.The company posted record adjusted net income attributable to shareholders , excluding most one-time items, of US$94.8 million, or US$0.12 per share, up from US$8.1 million, or US$0.01 per share, a year earlier. The result exceeded FactSet analysts' estimate of US$0.11 per share.Capstone said the increase was driven by stronger earnings from mining operations, supported by higher realized copper prices.Revenue for the three months ended March 31 rose to US$652.5 million from US$533.3 million in the prior-year period, beating FactSet analysts' estimate of US$647.5 million.The company also reported record adjusted EBITDA of US$329.1 million for Q1 2026, up from US$179.9 million a year earlier, primarily due to higher realized copper prices, which rose 36% to US$5.92 per pound, and supported by stronger gold and silver prices. This marked the sixth consecutive quarter of record adjusted EBITDA, the company said.In its 2026 production outlook, the company issued guidance of 200,000 to 230,000 tonnes of copper and C1 cash costs guidance of $2.45 to $2.75 per payable pound of copper remains unchanged. 2026 capital expenditure, capitalized stripping, and exploration expenditure guidance is also unchanged."We continue to monitor and manage the impacts stemming from the conflict in the Middle East. To date we have not experienced any inventory or operational impacts, however cost pressures, notably from higher diesel and sulphuric acid prices, represent a headwind," Capstone said.The company said its MV Optimized Project progressed according to plan during Q1 2026 and the capital cost estimate of US$176 million is unchanged. MV Optimized is a capital-efficient brownfield expansion project providing incremental copper and gold production of approximately 20,000 tonnes and 6,000 ounces of gold per annum, respectively."For the remainder of 2026, we are focused on operational execution and continuing to advance our high-return organic growth opportunities, including executing the Mantoverde Optimized Project, advancing Santo Domingo to a sanctioning decision, and progressing our exploration strategy centered around district-scale growth. Despite recent geopolitical volatility, copper prices remain strong and fundamentals support continued momentum, reinforcing our ability to deliver significant value through our peer-leading growth pipeline," chief executive Cashel Meagher said,Company's shares closed down $0.21 to $10.84 on Toronto Stock Exchange.

$CS.TO
Solid Biosciences Says SGT-003 Gets EU Orphan Drug Designation for Duchenne Muscular Dystrophy | FINWIRES